Volume 28, Number 3—March 2022
Research Letter
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
Seonju Yi1, Young June Choe1, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, and Young-Joon Park
Table
Severe acute respiratory syndrome coronavirus 2 breakthrough infections by vaccine type, South Korea, 2021
| Variable | ChAdOx1 nCov-19, AstraZeneca, prime/booster |
BNT162b2, Pfizer-BioNTech, prime/booster | Ad26.COV2.S, Johnson & Johnson/Janssen, single dose | mRNA-1273, Moderna, prime/booster | ChAdOx1 nCov-19/BNT162b2, AstraZeneca/Pfizer-BioNTech, prime/booster |
|---|---|---|---|---|---|
| Observed period | Apr 7–Oct 10 | Apr 3–Oct 10 | Jun 24–Oct 1 | Jul 30–Oct 10 | Jul 19–Oct 10 |
| Total vaccinations, no. | 8,737,343 | 10,235,891 | 1,408,921 | 1,190,973 | 1,600,998 |
| Breakthrough infections* | 21.7 | 8.5 | 42.6 | 1.8 | 21.3 |
| Serious outcomes* | 0.3 | 0.2 | 0.9 | 0.0 | 0.1 |
| Deaths* | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 |
| Secondary transmission* | 4.9 | 2.1 | 19.2 | 0.4 | 2.0 |
*Monthly age-adjusted rate per 100,000 population.
1These authors contributed equally to this article.
Page created: February 08, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.